Patents by Inventor Krzysztof Bartlomiej WICHER
Krzysztof Bartlomiej WICHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918647Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: GrantFiled: June 25, 2020Date of Patent: March 5, 2024Assignee: OSSIANIX, INC.Inventors: Julien Hasler, Julia Lynn Rutkowski, Krzysztof Bartlomiej Wicher
-
Publication number: 20240050581Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: ApplicationFiled: August 11, 2023Publication date: February 15, 2024Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Julia Lynn RUTKOWSKI, Fabrizio COMPER, Mykhaylo DEMYDCHUK, Jaroslaw Michal SZARY
-
Publication number: 20240026022Abstract: The present invention relates to a high affinity, VNAR polypeptide cross reactive with primate transferrin receptors (“TfR”). This TfR-specific VNAR polypeptide was obtained by screening semisynthetic VNAR phage display libraries against recombinant human TfR-1. The VNAR polypeptides of the invention can be used alone or as a component in conjugates that target the transferrin/transferrin receptor transport system. The invention further includes use of this VNAR, its conjugates and other derivatives in diagnostic and therapeutic methods, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier or other membrane systems. This TfR-specific VNAR polypeptide can also be used to target other biological barriers such the intestines, the placenta or aberrant cells overexpressing TfR-1, for therapeutic benefit in treatment of certain cancer cells and tumors of various tissue types.Type: ApplicationFiled: September 11, 2021Publication date: January 25, 2024Inventors: Pawel STOCKI, Jaroslaw Michal SZARY, Krzysztof Bartlomiej WICHER, Laura THEI, Julia Lynn RUTKOWSKI, Mykhaylo DEMYDCHUK, Shu-Fen COKER
-
Patent number: 11766482Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: GrantFiled: July 21, 2021Date of Patent: September 26, 2023Assignee: Ossianix, Inc.Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Julia Lynn Rutkowski, Fabrizio Comper, Mykhaylo Demydchuk, Jaroslaw Michal Szary
-
Publication number: 20230183369Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.Type: ApplicationFiled: October 27, 2022Publication date: June 15, 2023Applicant: OSSIANIX, INC.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Jaroslaw Michal SZARY, Julia Lynn RUTKOWSKI
-
Patent number: 11512136Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.Type: GrantFiled: October 27, 2018Date of Patent: November 29, 2022Assignee: Ossianix, Inc.Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Jaroslaw Michal Szary, Julia Lynn Rutkowski
-
Publication number: 20220177597Abstract: The present invention relates to CD98hc binding moieties with high specificity and with ability to cross the blood brain barrier (BBB). Such moieties may be used alone or as components in specific conjugates that target the amino acid transporter complexes formed with a light chain and CD98hc. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to CD98hc, compounds and compositions comprising a CD98hc-specific binding moiety, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a CD98hc-specific VNAR binding moiety. The invention also includes Type IV semi-synthetic VNAR libraries derived from shark VNARs for selection of binding moieties that specifically bind to a molecular or cellular target of interest.Type: ApplicationFiled: June 19, 2019Publication date: June 9, 2022Applicant: Ossianix, Inc.Inventors: Krzysztof Bartlomiej Wicher, Jaroslaw Michal Szary, Julia Lynn Rutkowski, Fabrizio Comper, Pawel Stocki
-
Publication number: 20220031857Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: ApplicationFiled: July 21, 2021Publication date: February 3, 2022Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Julia Lynn RUTKOWSKI, Fabrizio COMPER, Mykhaylo DEMYDCHUK, Jaroslaw Michal SZARY
-
Publication number: 20210403591Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.Type: ApplicationFiled: October 27, 2018Publication date: December 30, 2021Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Jaroslaw Michal SZARY, Julia Lynn RUTKOWSKI
-
Patent number: 11097010Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: GrantFiled: August 4, 2017Date of Patent: August 24, 2021Assignee: Ossianix, Inc.Inventors: Pawel Stocki, Krzysztof Bartlomiej Wicher, Julia Lynn Rutkowski, Fabrizio Comper, Mykhaylo Demydchuk, Jaroslaw Michal Szary
-
Publication number: 20200316195Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: ApplicationFiled: June 25, 2020Publication date: October 8, 2020Applicant: Ossianix, Inc.Inventors: Julien HASLER, Julia Lynn Rutkowski, Krzysztof Bartlomiej WICHER
-
Patent number: 10722576Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: GrantFiled: May 14, 2017Date of Patent: July 28, 2020Assignee: Ossianix, Inc.Inventors: Julien Häsler, Julia Lynn Rutkowski, Krzysztof Bartlomiej Wicher
-
Publication number: 20190175746Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.Type: ApplicationFiled: August 4, 2017Publication date: June 13, 2019Applicant: Ossianix, Inc.Inventors: Pawel STOCKI, Krzysztof Bartlomiej WICHER, Julia Lynn RUTKOWSKI, Fabrizio COMPER, Mykhaylo DEMYDCHUK, Jaroslaw Michal SZARY
-
Publication number: 20170348416Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety.Type: ApplicationFiled: May 14, 2017Publication date: December 7, 2017Applicant: Ossianix, Inc.Inventors: Julien HÄSLER, Julia Lynn RUTKOWSKI, Krzysztof Bartlomiej WICHER